Cardiac Dimensions commences commercialization of CARILLON mitral contour system in Europe

Cardiac Dimensions®, Inc. today announced that it has initiated its commercial efforts in Europe, treating the first patients with its CARILLON® Mitral Contour System® under its Conformite Europeenne (CE) Mark approval. The CARILLON system is a novel, minimally invasive therapy for treating heart patients suffering from functional mitral regurgitation (FMR). An estimated 70 percent of the 20 million people worldwide with heart failure also suffer from FMR.

As part of the commercial rollout, the patients have been enrolled in the PRIME (Percutaneous Repair in Functional Mitral Regurgitation) Study, a prospective, multicenter post-market study registry that builds on the clinical experience from Cardiac Dimensions' AMADEUS, TITAN and TITAN II studies. Long-term safety and efficacy will be evaluated in the PRIME study through the assessment of hemodynamics, functional capacity, heart failure hospitalizations as well as quality of life in up to 300 patients.

To support commercial efforts, Cardiac Dimensions has established direct operations in Europe, including a dedicated sales and clinical team focused exclusively on the successful rollout of the CARILLON system.

"Initiation of commercial sales represents a major milestone for Cardiac Dimensions," stated Rick Stewart, Chief Executive Officer. "We have spent the last few months preparing our organization for successful training, sales, distribution and clinical support of the CARILLON technology and are receiving a very warm reception from our early physician customers. In addition to general excitement around the minimally invasive CARILLON treatment, our physicians have also expressed a strong interest in participating in additional clinical studies. With the compelling outcomes expressed in TITAN and early positive signals coming from TITAN II, this bodes well as we begin the PRIME study."

Source:

Cardiac Dimensions, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study: 40% of newly diagnosed heart failure patients also have atrial fibrillation